JILL BRABANT: Open Payments
NPI 1326120692 · GOUVERNEUR, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$957 in 52 payments from 12 companies in 2025. Trend: 2023 $707 · 2024 $813 · 2025 $957
Food & beverage: $957
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 18 | $361 |
| Teva Pharmaceuticals USA, Inc. | 10 | $153 |
| Otsuka America Pharmaceutical, Inc. | 6 | $110 |
| ABBVIE INC. | 3 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Janssen Pharmaceuticals, Inc | 2 | $53 |
| Alkermes, Inc. | 3 | $46 |
| Vanda Pharmaceuticals Inc. | 3 | $45 |
| Lundbeck LLC | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
Products named: COBENFY, REXULTI, UZEDY, AUSTEDO XR, VRAYLAR, CAPLYTA, INVEGA SUSTENNA, LYBALVI.
Industry payments across NY — which companies pay providers there.
